查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1708005

全球癌症診斷市場：產業分析、規模、佔有率、成長、趨勢和預測（2025-2032）

Cancer Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 180 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現

  • 癌症診斷市場規模：1,378億美元（2025年）
  • 預計市場價值：2,227億美元（2032年）
  • 全球市場成長率：7.1%（2025年至2032年的複合年成長率）

癌症診斷市場 - 報告範圍

癌症診斷涵蓋了廣泛的工具、技術和程序，旨在早期發現癌症，以改善治療效果和存活率。該市場包括成像技術、切片檢查技術、腫瘤生物標記、分子診斷和就地檢驗系統。這些診斷方法用於醫院、病理實驗室和專科診所，以檢測各種類型的癌症，包括乳癌、肺癌、結腸癌、前列腺癌、子宮頸癌和血癌。推動市場成長的因素是全球癌症發生率的上升、早期發現意識的提高以及精準診斷和個人化醫療的進步。

市場成長動力

全球癌症診斷市場受到多種因素的推動，尤其是由於人口老化、生活方式的改變和環境因素導致全球癌症發病率的增加。透過先進的診斷技術進行早期檢測已顯著提高了存活率，推動了對創新解決方案的需求。次世代定序(NGS)、液態切片和人工智慧成像等技術進步正在改變癌症檢測並促進微創方法。政府支持癌症篩檢計畫的舉措、增加醫療保健支出以及腫瘤學伴同性診斷的日益普及正在進一步刺激市場擴張。

市場限制

儘管預計癌症診斷市場將經歷強勁成長，但它仍面臨多項挑戰，包括高昂的診斷成本，尤其是先進的分子和基因組測試。中低收入國家診斷設施的有限性阻礙了早期發現和治療。此外，癌症異質性和基因突變變化的複雜性需要不斷創新和臨床檢驗，從而增加開發成本和上市時間。監管障礙和報銷限制也會影響新診斷技術的商業性可行性。應對這些挑戰需要跨部門合作以及對經濟實惠、可擴展的診斷平台的有針對性的投資。

市場機會

由於技術創新以及人工智慧和機器學習在診斷中的作用不斷擴大，癌症診斷市場提供了巨大的成長機會。液態切片正在興起，並逐漸被接受為一種非侵入性、即時癌症監測工具。對生物標記發現、巨量資料分析整合和連接複用診斷平台開發的投資不斷增加，為個人化早期癌症診斷開闢了新的途徑。此外，更加關注家庭癌症篩檢工具和行動診斷可能會提高可近性和依從性，特別是在偏遠和服務不足的地區。

該報告研究了全球癌症診斷市場，並對市場動態進行了詳細分析，包括成長動力、趨勢、機會和挑戰。

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 任務
    • 主要趨勢
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值考慮

  • 價值鏈分析
  • 診斷測試採用/利用率分析
  • 癌症盛行率和發生率
  • 政府在癌症診斷方面的措施和資金
  • 主要市場公司
  • 監管格局
  • PESTLE分析
  • 波特五力分析
  • 消費行為分析

第4章全球癌症診斷市場展望

  • 主要亮點
    • 市場規模及與前一年同期比較
    • 絕對的商機
  • 市場規模分析及預測
    • 市場規模表現分析（2019-2024）
    • 當前市場規模分析與預測（2025-2032）
  • 全球癌症診斷市場展望：診斷測試
    • 診斷測試市場規模表現分析（2019-2024）
    • 診斷測試的當前市場規模分析和預測（2025-2032）
    • 市場吸引力分析：診斷測試
  • 全球癌症診斷市場展望：形態學
    • 按類型分類的市場規模表現分析（2019-2024）
    • 目前市場規模分析及按類型預測（2025-2032）
    • 市場吸引力分析：形式
  • 全球癌症診斷市場展望：應用
    • 市場規模績效分析：按應用（2019-2024）
    • 目前市場規模分析及應用預測（2025-2032）
    • 市場吸引力分析：應用
  • 全球癌症診斷市場展望：最終用途
    • 依最終用途分類的市場規模績效分析（2019-2024 年）
    • 目前市場規模分析及最終用途預測（2025-2032）
    • 市場吸引力分析：最終用途

第5章全球癌症診斷市場展望區域

  • 市場規模績效分析：按地區（2019-2024）
  • 目前市場規模分析及各地區預測（2025-2032）
    • 北美洲
    • 拉丁美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 中東和非洲
  • 市場吸引力分析：地區

6. 北美癌症診斷市場展望

7. 歐洲癌症診斷市場展望

第8章東亞癌症診斷市場展望

9. 南亞和大洋洲癌症診斷市場展望

第10章拉丁美洲癌症診斷市場展望

第 11 章中東和非洲癌症診斷市場展望

第12章競爭格局

  • 市場佔有率分析（2025年）
  • 市場結構
    • 競爭強度圖：按市場
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Illumina Inc.
    • bioMerieux SA
    • Qiagen
    • Siemens Healthineers
    • GE Healthcare
    • Hologic Inc.
    • Agilent Technologies Inc.
    • Becton, Dickinson and Company (BD)
    • Myriad Genetics Inc.
    • AstraZeneca
    • Regeneron
    • Novartis
    • BIO-RAD LABORATORIES
    • CANCER DIAGNOSTICS INC.
    • QUIDEL CORPORATION
    • Koninklijke Philips NV (Philips)
    • 其他

第13章 附錄

簡介目錄
Product Code: PMRREP35187

Persistence Market Research has recently released a comprehensive report on the worldwide market for cancer diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cancer diagnostics market from 2025 to 2032.

Key Insights:

  • Cancer Diagnostics Market Size (2025E): USD 137.8 Billion
  • Projected Market Value (2032F): USD 222.7 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 7.1%

Cancer Diagnostics Market - Report Scope:

Cancer diagnostics encompass a wide range of tools, technologies, and procedures aimed at detecting cancer at early stages to improve treatment outcomes and survival rates. The market includes imaging technologies, biopsy techniques, tumor biomarkers, molecular diagnostics, and point-of-care testing systems. These diagnostics are utilized across hospitals, pathology labs, and specialty clinics to detect various types of cancer, including breast, lung, colorectal, prostate, cervical, and blood cancers. Market growth is driven by the rising global cancer burden, increasing awareness about early detection, and ongoing advancements in precision diagnostics and personalized medicine.

Market Growth Drivers:

The global cancer diagnostics market is propelled by multiple factors, notably the increasing incidence of cancer worldwide due to aging populations, lifestyle changes, and environmental factors. Early detection through advanced diagnostic technologies significantly improves survival rates, driving demand for innovative solutions. Technological advancements such as next-generation sequencing (NGS), liquid biopsy, and AI-powered diagnostic imaging are transforming cancer detection and facilitating minimally invasive approaches. Government initiatives supporting cancer screening programs, rising healthcare expenditure, and the growing adoption of companion diagnostics in oncology further stimulate market expansion.

Market Restraints:

Despite robust growth prospects, the cancer diagnostics market faces several challenges, including high diagnostic costs, especially for advanced molecular and genomic tests. Limited access to diagnostic facilities in low- and middle-income countries impedes early detection and treatment. Additionally, the complexity of cancer heterogeneity and evolving genetic mutations requires continuous innovation and clinical validation, raising development costs and time-to-market. Regulatory hurdles and reimbursement constraints also impact the commercial viability of emerging diagnostic technologies. Addressing these challenges necessitates cross-sector collaboration and targeted investment in affordable, scalable diagnostic platforms.

Market Opportunities:

The cancer diagnostics market presents significant growth opportunities driven by technological innovations and the expanding role of artificial intelligence and machine learning in diagnostics. The emergence of liquid biopsy as a non-invasive, real-time cancer monitoring tool is gaining traction. Growing investments in biomarker discovery, integration of big data analytics, and the development of multiplex diagnostic platforms open new avenues for personalized and early-stage cancer diagnostics. Moreover, increased focus on home-based cancer screening tools and mobile diagnostics can improve accessibility and compliance, especially in remote or underserved areas.

Key Questions Answered in the Report:

  • What are the key factors contributing to the global growth of the cancer diagnostics market?
  • Which diagnostic technologies and cancer types are driving market demand across various regions?
  • How are innovations in molecular diagnostics and AI reshaping the competitive dynamics of the market?
  • Who are the leading players in the cancer diagnostics market, and what strategies are they adopting for market leadership?
  • What are the emerging trends and future opportunities in the global cancer diagnostics landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global cancer diagnostics market, such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company, are actively investing in R&D, strategic collaborations, and acquisitions to enhance their diagnostic portfolios. These companies focus on developing comprehensive cancer detection platforms combining genetic, proteomic, and imaging-based technologies. Collaborations with pharmaceutical firms for companion diagnostics and personalized treatment regimens are key strategic moves. In addition, companies are expanding their geographic presence through partnerships with local healthcare providers and governments to address the rising demand for cancer diagnostics across emerging markets.

Key Companies Profiled:

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • bioMerieux SA
  • Qiagen
  • Siemens Healthineers
  • GE Healthcare
  • Hologic Inc.
  • Koninklijke Philips N.V. (Philips)
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company (BD)
  • Myriad Genetics Inc.
  • AstraZeneca
  • Regeneron
  • Novartis
  • Bio-Rad Laboratories
  • Cancer Diagnostics Inc.
  • Quidel Corporation
  • Others

Market Segmentation

By Diagnostic Test

  • Biomarker Test
  • Prostate-Specific Antigen (PSA)
  • Circulating Tumor Cells (CTC)
  • Alpha-Fetoprotein (AFP)
  • Cancer Antigen 125 (CA-125)
  • HER2
  • Other
  • Imaging Technology
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Others
  • Endoscopy
  • Colonoscopy
  • Biopsy
  • Others

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Other

By End-Use

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Ambulatory Surgical Centers

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Cancer Diagnostics Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Value Chain Analysis
  • 3.2. Diagnostic Test Adoption / Usage Analysis
  • 3.3. Prevalence & Incidence of Cancer
  • 3.4. Government Initiatives & Funding in Cancer Diagnostics
  • 3.5. Key Market Players
  • 3.6. Regulatory Landscape
  • 3.7. PESTLE Analysis
  • 3.8. Porter's Five Force Analysis
  • 3.9. Consumer Behavior Analysis

4. Global Cancer Diagnostics Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Cancer Diagnostics Market Outlook Diagnostic Test
    • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2024
    • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
      • 4.3.2.1. Biomarker Test
        • 4.3.2.1.1. Prostate-Specific Antigen (PSA)
        • 4.3.2.1.2. Circulating Tumor Cells (CTC)
        • 4.3.2.1.3. Alpha-Fetoprotein (AFP)
        • 4.3.2.1.4. Cancer Antigen 125 (CA-125)
        • 4.3.2.1.5. HER2
        • 4.3.2.1.6. Other
      • 4.3.2.2. Imaging Technology
        • 4.3.2.2.1. Magnetic Resonance Imaging (MRI)
        • 4.3.2.2.2. Computed Tomography (CT)
        • 4.3.2.2.3. Positron Emission Tomography (PET)
        • 4.3.2.2.4. Mammography
        • 4.3.2.2.5. Others
      • 4.3.2.3. Endoscopy
      • 4.3.2.4. Colonoscopy
      • 4.3.2.5. Biopsy
      • 4.3.2.6. Others
    • 4.3.3. Market Attractiveness Analysis: Diagnostic Test
  • 4.4. Global Cancer Diagnostics Market Outlook Form
    • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Form, 2019-2024
    • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Form, 2025-2032
      • 4.4.2.1. Isolates
      • 4.4.2.2. Concentrates
      • 4.4.2.3. Hydrolysates
    • 4.4.3. Market Attractiveness Analysis: Form
  • 4.5. Global Cancer Diagnostics Market Outlook Application
    • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.2.1. Lung Cancer
      • 4.5.2.2. Breast Cancer
      • 4.5.2.3. Prostate Cancer
      • 4.5.2.4. Colorectal Cancer
      • 4.5.2.5. Melanoma Cancer
      • 4.5.2.6. Blood Cancer
      • 4.5.2.7. Ovarian Cancer
      • 4.5.2.8. Other
    • 4.5.3. Market Attractiveness Analysis: Application
  • 4.6. Global Cancer Diagnostics Market Outlook End-use
    • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
    • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
      • 4.6.2.1. Hospitals
      • 4.6.2.2. Diagnostic Laboratories
      • 4.6.2.3. Cancer Research Institutes
      • 4.6.2.4. Ambulatory Surgical Centers
    • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Cancer Diagnostics Market Outlook Region

  • 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.2.1. North America
    • 5.2.2. Latin America
    • 5.2.3. Europe
    • 5.2.4. East Asia
    • 5.2.5. South Asia and Oceania
    • 5.2.6. Middle East & Africa
  • 5.3. Market Attractiveness Analysis: Region

6. North America Cancer Diagnostics Market Outlook

  • 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.1.1. By Country
    • 6.1.2. By Diagnostic Test
    • 6.1.3. By Application
    • 6.1.4. By End-use
  • 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 6.3.1. Biomarker Test
      • 6.3.1.1. Prostate-Specific Antigen (PSA)
      • 6.3.1.2. Circulating Tumor Cells (CTC)
      • 6.3.1.3. Alpha-Fetoprotein (AFP)
      • 6.3.1.4. Cancer Antigen 125 (CA-125)
      • 6.3.1.5. HER2
      • 6.3.1.6. Other
    • 6.3.2. Imaging Technology
      • 6.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.3.2.2. Computed Tomography (CT)
      • 6.3.2.3. Positron Emission Tomography (PET)
      • 6.3.2.4. Mammography
      • 6.3.2.5. Others
    • 6.3.3. Endoscopy
    • 6.3.4. Colonoscopy
    • 6.3.5. Biopsy
    • 6.3.6. Others
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.4.1. Lung Cancer
    • 6.4.2. Breast Cancer
    • 6.4.3. Prostate Cancer
    • 6.4.4. Colorectal Cancer
    • 6.4.5. Melanoma Cancer
    • 6.4.6. Blood Cancer
    • 6.4.7. Ovarian Cancer
    • 6.4.8. Other
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 6.5.1. Hospitals
    • 6.5.2. Diagnostic Laboratories
    • 6.5.3. Cancer Research Institutes
    • 6.5.4. Ambulatory Surgical Centers
  • 6.6. Market Attractiveness Analysis

7. Europe Cancer Diagnostics Market Outlook

  • 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Diagnostic Test
    • 7.1.3. By Form
    • 7.1.4. By Application
    • 7.1.5. By End-use
  • 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Russia
    • 7.2.7. Rest of Europe
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 7.3.1. Biomarker Test
      • 7.3.1.1. Prostate-Specific Antigen (PSA)
      • 7.3.1.2. Circulating Tumor Cells (CTC)
      • 7.3.1.3. Alpha-Fetoprotein (AFP)
      • 7.3.1.4. Cancer Antigen 125 (CA-125)
      • 7.3.1.5. HER2
      • 7.3.1.6. Other
    • 7.3.2. Imaging Technology
      • 7.3.2.1. Magnetic Resonance Imaging (MRI)
      • 7.3.2.2. Computed Tomography (CT)
      • 7.3.2.3. Positron Emission Tomography (PET)
      • 7.3.2.4. Mammography
      • 7.3.2.5. Others
    • 7.3.3. Endoscopy
    • 7.3.4. Colonoscopy
    • 7.3.5. Biopsy
    • 7.3.6. Others
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Prostate Cancer
    • 7.4.4. Colorectal Cancer
    • 7.4.5. Melanoma Cancer
    • 7.4.6. Blood Cancer
    • 7.4.7. Ovarian Cancer
    • 7.4.8. Other
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 7.5.1. Hospitals
    • 7.5.2. Diagnostic Laboratories
    • 7.5.3. Cancer Research Institutes
    • 7.5.4. Ambulatory Surgical Centers
  • 7.6. Market Attractiveness Analysis

8. East Asia Cancer Diagnostics Market Outlook

  • 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Diagnostic Test
    • 8.1.3. By Application
    • 8.1.4. By End-use
  • 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.2.1. China
    • 8.2.2. Japan
    • 8.2.3. South Korea
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 8.3.1. Biomarker Test
      • 8.3.1.1. Prostate-Specific Antigen (PSA)
      • 8.3.1.2. Circulating Tumor Cells (CTC)
      • 8.3.1.3. Alpha-Fetoprotein (AFP)
      • 8.3.1.4. Cancer Antigen 125 (CA-125)
      • 8.3.1.5. HER2
      • 8.3.1.6. Other
    • 8.3.2. Imaging Technology
      • 8.3.2.1. Magnetic Resonance Imaging (MRI)
      • 8.3.2.2. Computed Tomography (CT)
      • 8.3.2.3. Positron Emission Tomography (PET)
      • 8.3.2.4. Mammography
      • 8.3.2.5. Others
    • 8.3.3. Endoscopy
    • 8.3.4. Colonoscopy
    • 8.3.5. Biopsy
    • 8.3.6. Others
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.4.1. Lung Cancer
    • 8.4.2. Breast Cancer
    • 8.4.3. Prostate Cancer
    • 8.4.4. Colorectal Cancer
    • 8.4.5. Melanoma Cancer
    • 8.4.6. Blood Cancer
    • 8.4.7. Ovarian Cancer
    • 8.4.8. Other
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 8.5.1. Hospitals
    • 8.5.2. Diagnostic Laboratories
    • 8.5.3. Cancer Research Institutes
    • 8.5.4. Ambulatory Surgical Centers
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Cancer Diagnostics Market Outlook

  • 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Diagnostic Test
    • 9.1.3. By Application
    • 9.1.4. By End-use
  • 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.2.1. India
    • 9.2.2. Indonesia
    • 9.2.3. Thailand
    • 9.2.4. Singapore
    • 9.2.5. ANZ
    • 9.2.6. Rest of South Asia & Oceania
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 9.3.1. Biomarker Test
      • 9.3.1.1. Prostate-Specific Antigen (PSA)
      • 9.3.1.2. Circulating Tumor Cells (CTC)
      • 9.3.1.3. Alpha-Fetoprotein (AFP)
      • 9.3.1.4. Cancer Antigen 125 (CA-125)
      • 9.3.1.5. HER2
      • 9.3.1.6. Other
    • 9.3.2. Imaging Technology
      • 9.3.2.1. Magnetic Resonance Imaging (MRI)
      • 9.3.2.2. Computed Tomography (CT)
      • 9.3.2.3. Positron Emission Tomography (PET)
      • 9.3.2.4. Mammography
      • 9.3.2.5. Others
    • 9.3.3. Endoscopy
    • 9.3.4. Colonoscopy
    • 9.3.5. Biopsy
    • 9.3.6. Others
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.4.1. Lung Cancer
    • 9.4.2. Breast Cancer
    • 9.4.3. Prostate Cancer
    • 9.4.4. Colorectal Cancer
    • 9.4.5. Melanoma Cancer
    • 9.4.6. Blood Cancer
    • 9.4.7. Ovarian Cancer
    • 9.4.8. Other
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 9.5.1. Hospitals
    • 9.5.2. Diagnostic Laboratories
    • 9.5.3. Cancer Research Institutes
    • 9.5.4. Ambulatory Surgical Centers
  • 9.6. Market Attractiveness Analysis

10. Latin America Cancer Diagnostics Market Outlook

  • 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Diagnostic Test
    • 10.1.3. By Application
    • 10.1.4. By End-use
  • 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of Latin America
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 10.3.1. Biomarker Test
      • 10.3.1.1. Prostate-Specific Antigen (PSA)
      • 10.3.1.2. Circulating Tumor Cells (CTC)
      • 10.3.1.3. Alpha-Fetoprotein (AFP)
      • 10.3.1.4. Cancer Antigen 125 (CA-125)
      • 10.3.1.5. HER2
      • 10.3.1.6. Other
    • 10.3.2. Imaging Technology
      • 10.3.2.1. Magnetic Resonance Imaging (MRI)
      • 10.3.2.2. Computed Tomography (CT)
      • 10.3.2.3. Positron Emission Tomography (PET)
      • 10.3.2.4. Mammography
      • 10.3.2.5. Others
    • 10.3.3. Endoscopy
    • 10.3.4. Colonoscopy
    • 10.3.5. Biopsy
    • 10.3.6. Others
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.4.1. Lung Cancer
    • 10.4.2. Breast Cancer
    • 10.4.3. Prostate Cancer
    • 10.4.4. Colorectal Cancer
    • 10.4.5. Melanoma Cancer
    • 10.4.6. Blood Cancer
    • 10.4.7. Ovarian Cancer
    • 10.4.8. Other
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 10.5.1. Hospitals
    • 10.5.2. Diagnostic Laboratories
    • 10.5.3. Cancer Research Institutes
    • 10.5.4. Ambulatory Surgical Centers
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Cancer Diagnostics Market Outlook

  • 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Diagnostic Test
    • 11.1.3. By Application
    • 11.1.4. By End-use
  • 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.2.1. GCC Countries
    • 11.2.2. Egypt
    • 11.2.3. South Africa
    • 11.2.4. Northern Africa
    • 11.2.5. Rest of Middle East & Africa
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 11.3.1. Biomarker Test
      • 11.3.1.1. Prostate-Specific Antigen (PSA)
      • 11.3.1.2. Circulating Tumor Cells (CTC)
      • 11.3.1.3. Alpha-Fetoprotein (AFP)
      • 11.3.1.4. Cancer Antigen 125 (CA-125)
      • 11.3.1.5. HER2
      • 11.3.1.6. Other
    • 11.3.2. Imaging Technology
      • 11.3.2.1. Magnetic Resonance Imaging (MRI)
      • 11.3.2.2. Computed Tomography (CT)
      • 11.3.2.3. Positron Emission Tomography (PET)
      • 11.3.2.4. Mammography
      • 11.3.2.5. Others
    • 11.3.3. Endoscopy
    • 11.3.4. Colonoscopy
    • 11.3.5. Biopsy
    • 11.3.6. Others
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.4.1. Lung Cancer
    • 11.4.2. Breast Cancer
    • 11.4.3. Prostate Cancer
    • 11.4.4. Colorectal Cancer
    • 11.4.5. Melanoma Cancer
    • 11.4.6. Blood Cancer
    • 11.4.7. Ovarian Cancer
    • 11.4.8. Other
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Laboratories
    • 11.5.3. Cancer Research Institutes
    • 11.5.4. Ambulatory Surgical Centers
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. F. Hoffmann-La Roche Ltd
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Sources
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
    • 12.3.3. Abbott Laboratories
    • 12.3.4. Illumina Inc.
    • 12.3.5. bioMerieux SA
    • 12.3.6. Qiagen
    • 12.3.7. Siemens Healthineers
    • 12.3.8. GE Healthcare
    • 12.3.9. Hologic Inc.
    • 12.3.10. Agilent Technologies Inc.
    • 12.3.11. Becton, Dickinson and Company (BD)
    • 12.3.12. Myriad Genetics Inc.
    • 12.3.13. AstraZeneca
    • 12.3.14. Regeneron
    • 12.3.15. Novartis
    • 12.3.16. BIO-RAD LABORATORIES
    • 12.3.17. CANCER DIAGNOSTICS INC.
    • 12.3.18. QUIDEL CORPORATION
    • 12.3.19. Koninklijke Philips N.V. (Philips)
    • 12.3.20. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations